Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3775 - Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Translational Research;  Pancreatic Cancer

Presenters

Caterina Vivaldi

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

C. Vivaldi1, E. Arrigoni2, R. Morganti3, S. Catanese1, L. Fidilio2, I. Pecora1, G. Restante2, L. Fornaro1, S. Crucitta2, M. Lencioni1, E. Rofi2, E. Vasile1, A. Falcone1, R. Danesi2, M. Del Re2

Author affiliations

  • 1 University Hospital Of Pisa, Medical Oncology Unit, 56100 - Pisa/IT
  • 2 Department Of Clinical And Experimental Medicine, University Hospital Of Pisa, Clinical Pharmacology and Pharmacogenetics Unit, Pisa/IT
  • 3 Department Of Clinical And Experimental Medicine, University Hospital Of Pisa, Section of Statistics, Pisa/IT
More

Resources

Abstract 3775

Background

Modified FOLFIRINOX (mFOLFIRINOX) is a standard treatment in advanced pancreatic cancer (aPC). Because of the presence of either loss-of-function mutations in DPYD (c.1679T>G, IVS14 + 1G>A, c.2194G>A, c.2846A>T) or UGT1A1*28 variant associated with reduced UGT1A1 expression, deficiency of DPD and UGT may result in drug accumulation and severe toxicities caused by fluoropyrimidines and irinotecan, respectively.

Methods

The present study analyzes the association between DPYD and UGT variants and adverse drug reactions (ADRs) in aPC patients (pts) treated with mFOLFIRINOX. Blood samples were collected from 104 pts, and analyses of DPYD c.1679T>G, IVS14 + 1G>A, c.2194G>A, c.2846A>T and UGT1A1*28 were performed by automatic sequencing. Statistical analysis was performed by chi-square, Mann-Whitney and Spearman's rho tests on SPSS v.23s.

Results

None of the pts was carrier of the c.1679G and c.2846T alleles. Only one IVS14 + 1GA was found and 8 pts had c.2194GA genotype. ADRs grade (G) ≥3 were neutropenia (42.3%), diarrhea (7.7%) and stomatitis (7.7%). The statistical analysis of the IVS14 + 1GA has not been performed due to the extremely low frequency of the mutant allele (0.96%), however IVS14 + 1GA patient experienced G4 hematological and gastrointestinal ADRs after the first cycle. We observed a trend toward significant association between c.2194GA genotype and the risk of thrombocytopenia (p = 0.080) and hand-foot syndrome (HFS) (p = 0.096). The UGT1A1*28 allele was found in 56 (54.4%) pts (*1/*28, n = 38; *28/*28, n = 18) and it was correlated with the risk of developing thrombocytopenia (p = 0.006) and neutropenia (p = 0.044). Moreover, this risk increased as the number of *28 alleles increased (*28/*28 > *1/*28 > *1/*1, p = 0.003). No significant correlation with diarrhea was found.

Conclusions

Our data confirm that DPYD IVS14 + 1A is associated with life-threatening toxicities and that the c.2194A allele could be possibly associated with thrombocytopenia and HFS, but validation in larger cohorts is needed. UGT1A1*28 allele is associated with a higher risk of G3/4 thrombocytopenia and neutropenia, and should be implemented in routine practice to personalize treatment in aPC.

Clinical trial identification

Legal entity responsible for the study

University of Pisa

Funding

Institutional fundings

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.